Evidence map›Paper›PMID 23103869›Full record

ArticleNature2012

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.

Andrew V Biankin, Nicola Waddell, Karin S Kassahn, Marie-Claude Gingras, Lakshmi B Muthuswamy, Amber L Johns, David K Miller, Peter J Wilson, Ann-Marie Patch, Jianmin Wu and 117 more

2 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in Nature, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1,266 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,266citing papers in PubMed, 1 pooled it
68.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02869802 recruitingnot on this mapstarted 2016, after this paper: background citation

Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis

TypeobservationalSponsorBritish Columbia Cancer AgencyRan2016 to 2027Enrolled190ConditionsCancer, Pancreatic CancerArmsTumour Biopsy, Serial Collection of Plasma and Serum Samples
NCT06736717 phase1 / phase2recruitingnot on this mapstarted 2025, after this paper: background citation

A Phase 1b/2 Trial of Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer

TypeinterventionalSponsorUniversity of Kansas Medical CenterRan2025 to 2027Enrolled21ConditionsPancreatic CancerArmsOnvansertib, NALIRIFOX
3 · Its place in the literature

Who cites it

1,266 citing papers in PubMed, 1 synthesis or guideline pooled it, 2,093 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. SWI/SNF Complex-Deficient Undifferentiated Carcinoma of the Pancreas: Clinicopathologic and Genomic Analysis.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2024
    Trial
  4. Review
  5. Article
  6. Article
  7. The CaThe Journal of biological chemistry · 2026
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. SuppressedInternational journal of molecular sciences · 2026
    Article
  19. Article
  20. Article

1,206 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

127 authors at 15 institutions in 6 countries.

Andrew V BiankinThe Kinghorn Cancer Centre, 370 Victoria Street, Darlinghurst, Sydney, New South Wales 2010, Australia.
Nicola Waddell
Karin S Kassahn
Marie-Claude Gingras
Lakshmi B Muthuswamy
Amber L Johns
David K Miller
Peter J Wilson
Ann-Marie Patch
Jianmin Wu
David K Chang
Mark J Cowley
Brooke B Gardiner
Sarah Song
Ivon Harliwong
Senel Idrisoglu
Craig Nourse
Ehsan Nourbakhsh
Suzanne Manning
Shivangi Wani
Milena Gongora
Marina Pajic
Christopher J Scarlett
Anthony J Gill
Andreia V Pinho
Ilse Rooman
Matthew Anderson
Oliver Holmes
Conrad Leonard
Darrin Taylor
Scott Wood
Qinying Xu
Katia Nones
J Lynn Fink
Angelika Christ
Tim Bruxner
Nicole Cloonan
Gabriel Kolle
Felicity Newell
Mark Pinese
R Scott Mead
Jeremy L Humphris
Warren Kaplan
Marc D Jones
Emily K Colvin
Adnan M Nagrial
Emily S Humphrey
Angela Chou
Venessa T Chin
Lorraine A Chantrill
Amanda Mawson
Jaswinder S Samra
James G Kench
Jessica A Lovell
Roger J Daly
Neil D Merrett
Christopher Toon
Krishna Epari
Nam Q Nguyen
Andrew Barbour
Nikolajs Zeps
Australian Pancreatic Cancer Genome Initiative
Nipun Kakkar
Fengmei Zhao
Yuan Qing Wu
Min Wang
Donna M Muzny
William E Fisher
F Charles Brunicardi
Sally E Hodges
Jeffrey G Reid
Jennifer Drummond
Kyle Chang
Yi Han
Lora R Lewis
Huyen Dinh
Christian J Buhay
Timothy Beck
Lee Timms
Michelle Sam
Kimberly Begley
Andrew Brown
Deepa Pai
Ami Panchal
Nicholas Buchner
Richard De Borja
Robert E Denroche
Christina K Yung
Stefano Serra
Nicole Onetto
Debabrata Mukhopadhyay
Ming-Sound Tsao
Patricia A Shaw
Gloria M Petersen
Steven Gallinger
Ralph H Hruban
Anirban Maitra
Christine A Iacobuzio-Donahue
Richard D Schulick
Christopher L Wolfgang
Richard A Morgan
Rita T Lawlor
Paola Capelli
Vincenzo Corbo
Maria Scardoni
Giampaolo Tortora
Margaret A Tempero
Karen M Mann
Nancy A Jenkins
Pedro A Perez-Mancera
David J Adams
David A Largaespada
Lodewyk F A Wessels
Alistair G Rust
Lincoln D Stein
David A Tuveson
Neal G Copeland
Elizabeth A Musgrove
Aldo Scarpa
James R Eshleman
Thomas J Hudson
Robert L Sutherland
David A Wheeler
John V Pearson
John D McPherson
Richard A Gibbs
Sean M Grimmond
Garvan Institute of Medical Research · AUThe University of Queensland · AUOntario Institute for Cancer Research · CABaylor College of Medicine · USUniversity of Verona · ITJohns Hopkins University · USHouston Methodist · USUniversity Health Network · CAThe University of Sydney · AURoyal Adelaide Hospital · AUSt John of God Subiaco Hospital · AUUniversity of Minnesota · USCancer Research UK · GBMount Sinai Hospital · CAWellcome Sanger Institute · GB

Funding

The Human Genome Sequencing CenterU54HG003273 · NHGRI · BAYLOR COLLEGE OF MEDICINE · PI GIBBS, RICHARD A · 2004 to 2015
$341.3M
Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI LENNON, ANNE MARIE · 1993 to 2022
$54.6M
Tissue CoreP50CA102701 · NCI · MAYO CLINIC ROCHESTER · PI PETERSEN, GLORIA M. · 2004 to 2018
$32.7M
Pancreatic Cancer Genetic Epidemiology Consortium (PACGENE)R01CA097075 · NCI · MAYO CLINIC ROCHESTER · PI PETERSEN, GLORIA M. · 2002 to 2012
$15.8M
UAB / UMN SPORE in Pancreatic CancerP50CA101955 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BUCHSBAUM, DONALD J · 2010 to 2014
$11.1M
Zebrafish CoreP01CA134292 · NCI · JOHNS HOPKINS UNIVERSITY · PI LEACH, STEVEN D · 2009 to 2013
$7.4M
Sleeping Beauty for uncovering cancer genes in miceR01CA113636 · NCI · UNIVERSITY OF MINNESOTA · PI LARGAESPADA, DAVID ANDREW · 2006 to 2016
$2.5M
Cancer Research UK 13031NCI NIH HHS 2P50CA101955NCI NIH HHS P01 CA134292NCI NIH HHS P01CA134292NCI NIH HHS P50 CA062924NCI NIH HHS P50CA062924NCI NIH HHS P50 CA101955NCI NIH HHS P50 CA102701NCI NIH HHS R01 CA097075NCI NIH HHS R01 CA113636NCI NIH HHS R01 CA97075NHGRI NIH HHS U54 HG003273Wellcome Trust
6 · The paper itself

Abstract

Pancreatic cancer is a highly lethal malignancy with few effective therapies. We performed exome sequencing and copy number analysis to define genomic aberrations in a prospectively accrued clinical cohort (n = 142) of early (stage I and II) sporadic pancreatic ductal adenocarcinoma. Detailed analysis of 99 informative tumours identified substantial heterogeneity with 2,016 non-silent mutations and 1,628 copy-number variations. We define 16 significantly mutated genes, reaffirming known mutations (KRAS, TP53, CDKN2A, SMAD4, MLL3, TGFBR2, ARID1A and SF3B1), and uncover novel mutated genes including additional genes involved in chromatin modification (EPC1 and ARID2), DNA damage repair (ATM) and other mechanisms (ZIM2, MAP2K4, NALCN, SLC16A4 and MAGEA6). Integrative analysis with in vitro functional data and animal models provided supportive evidence for potential roles for these genetic aberrations in carcinogenesis. Pathway-based analysis of recurrently mutated genes recapitulated clustering in core signalling pathways in pancreatic ductal adenocarcinoma, and identified new mutated genes in each pathway. We also identified frequent and diverse somatic aberrations in genes described traditionally as embryonic regulators of axon guidance, particularly SLIT/ROBO signalling, which was also evident in murine Sleeping Beauty transposon-mediated somatic mutagenesis models of pancreatic cancer, providing further supportive evidence for the potential involvement of axon guidance genes in pancreatic carcinogenesis.

Indexed as

AnimalsAxonsCarcinoma, Pancreatic DuctalGene DosageGene Expression Regulation, NeoplasticGenomeHumansKaplan-Meier EstimateMiceMutationPancreatic NeoplasmsProteinsSignal TransductionProteins

Identifiers

PMID23103869
PMCPMC3530898
OpenAlexW2161884651

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.